報價延遲最少15分鐘:2026/03/05 11:33 EST
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
34.475 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
0.82/2.51
|
|
企業價值
3.80B
|
| 資產負債 |
|
每股賬面淨值
6.09
|
| 現金流量 |
|
現金流量率
0.03
|
| 損益表 |
|
收益
761.41M
|
|
每股收益
4.23
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH. |
